Literature DB >> 10790342

Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries.

N Sawada1, H Itoh, K Ueyama, J Yamashita, K Doi, T H Chun, M Inoue, K Masatsugu, T Saito, Y Fukunaga, S Sakaguchi, H Arai, N Ohno, M Komeda, K Nakao.   

Abstract

BACKGROUND: Rho-associated kinase (ROCK), an effector of small GTPase Rho, regulates vascular tone via a calcium sensitization mechanism and plays a key role in the pathogenesis of hypertension. However, its role in vascular growth remains unclear. METHODS AND
RESULTS: Y-27632, a specific ROCK inhibitor, and the overexpression of dominant-negative ROCK suppressed the mitogen-induced DNA synthesis of cultured vascular smooth muscle cells (VSMCs), which indicates the essential role of ROCK in the control of VSMC proliferation in vitro. Y-27632 also suppressed the chemotaxis of VSMCs. Male Wistar rats were systemically given Y-27632 (35 to 70 mg. kg(-1). day(-1)) through an intraperitoneal infusion. The neointimal formation of balloon-injured carotid arteries was significantly suppressed in Y-27632-treated rats (intima/media ratio, 0.22+/-0.02) compared with vehicle-treated rats (intima/media ratio, 0.92+/-0.21) or hydralazine-treated rats with a similar blood pressure decrease (intima/media ratio, 1.03+/-0.15). The phosphorylation of myosin phosphatase and myosin light chain was elevated in injured arteries in a Y-27632-sensitive manner, indicating the augmentation of ROCK activity in neointimal formation. The downregulation of the cyclin-dependent kinase inhibitor p27(kip1) in injured vessels was reversed by Y-27632 treatment, reflecting the antiproliferative effect of ROCK inhibition in vivo.
CONCLUSIONS: We conclude that ROCK plays a key role in the process of neointimal formation after balloon injury. Thus, the inhibition of ROCK may be a potential therapeutic strategy for treating vascular proliferative disorders and hypertension.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790342     DOI: 10.1161/01.cir.101.17.2030

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  54 in total

1.  Role of Rho kinase signalling in healthy and varicose human saphenous veins.

Authors:  Chrystelle Cario-Toumaniantz; Sandrine Evellin; Séverine Maury; Olivier Baron; Pierre Pacaud; Gervaise Loirand
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

2.  Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil.

Authors:  Takaki Hata; Chikara Goto; Junko Soga; Takayuki Hidaka; Yuichi Fujii; Naomi Idei; Noritaka Fujimura; Tatsuya Maruhashi; Shinsuke Mikami; Yasuki Kihara; Kazuaki Chayama; Kensuke Noma; James K Liao; Yukihito Higashi
Journal:  Atherosclerosis       Date:  2010-10-12       Impact factor: 5.162

Review 3.  "Venopathy" at work: recasting neointimal hyperplasia in a new light.

Authors:  Alexander S Yevzlin; Micah R Chan; Yolanda T Becker; Prabir Roy-Chaudhury; Timmy Lee; Bryan N Becker
Journal:  Transl Res       Date:  2010-08-13       Impact factor: 7.012

Review 4.  Pleiotropic effects of statin therapy: molecular mechanisms and clinical results.

Authors:  Chao-Yung Wang; Ping-Yen Liu; James K Liao
Journal:  Trends Mol Med       Date:  2008-01       Impact factor: 11.951

Review 5.  Rho kinase (ROCK) inhibitors.

Authors:  James K Liao; Minoru Seto; Kensuke Noma
Journal:  J Cardiovasc Pharmacol       Date:  2007-07       Impact factor: 3.105

6.  The effects of matrix stiffness and RhoA on the phenotypic plasticity of smooth muscle cells in a 3-D biosynthetic hydrogel system.

Authors:  Shelly R Peyton; Peter D Kim; Cyrus M Ghajar; Dror Seliktar; Andrew J Putnam
Journal:  Biomaterials       Date:  2008-03-14       Impact factor: 12.479

Review 7.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

Review 8.  Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.

Authors:  Naoki Sawada; James K Liao
Journal:  Antioxid Redox Signal       Date:  2013-09-24       Impact factor: 8.401

9.  A method for measuring Rho kinase activity in tissues and cells.

Authors:  Ping-Yen Liu; James K Liao
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

10.  Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.

Authors:  Ping-Yen Liu; Yen-Wen Liu; Li-Jen Lin; Jyh-Hong Chen; James K Liao
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.